Do aspirin or nonsteroidal antiinflammatory drugs decrease the risk of colorectal cancer?;La consommation d'aspirine ou d'anti-inflammatoires non steroidiens diminue-t-elle le risque de cancer colique?

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 3 BIS, 1998, Pages

  Benamouzig, Robert ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Aspirin; Colorectal carcinoma; Nonsteroidal antiinflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

CANCER RISK; CARCINOGENESIS; COHORT ANALYSIS; COLON POLYP; COLORECTAL CANCER; CONFERENCE PAPER; FAMILIAL POLYPOSIS; HUMAN; NONHUMAN; RECTUM POLYP; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS; HUMANS; RISK; SULINDAC;

EID: 0031809755     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Vainio H, Morgan G, Kleihues P. An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 1997;6:749-53.
2. Marcus AJ. Aspirin as prophylaxis against colorectal cancer. N Engl J Med 1995;333:656-8.
3. st ed. Lyon: International Agency for Research on Cancer. World Health Organization, 1997.
4. Benamouzig R, Chaussade S, Little J, Munoz N, Rautureau J, Couturier D. Aspirine, AINS et carcinogenèse colique. Gastroenterol Clin Biol 1997;21:188-96.
5. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D,L,a-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990;50:2562-8.
6. Craven PA, DeRubertis FR. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis 1992;13:541-6.
7. Narisawa T, Sato M, Sano M, Takahashi T. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 1981;41:1954-7.
8. Narisawa T, Satoh M, Sano M, Takahashi T. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 1983;4:1225-7.
9. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-7.
10. Gonzaga RAF, Lima FR, Carneiro S, Maciel J, Junior MA. Sulindac treatment for familial polyposis coli. Lancet 1985;1:751.
11. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.
12. Charneau JD, D'Aubigny N, Burtin P, Person B, Boyer J. Micropolypes rectaux après coleclomie totale pour polypose familiale. Efficacité du sulindac. Gastroenterol Clin Biol 1990;14:153-7.
13. Friend WG. Sulindac suppression of colorectal polyps in Gardner's syndrome. Am Fam Physician 1990;41:891-4.
14. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-4.
15. Tonelli F, Valanzano R. Sulindac in familial adenomatous polyposis. Lancet 1993;342:1120.
16. Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorect Dis 1993;8:13-7.
17. Makela JT, Laitinen S. Sulindac therapy for familial adenomatous polyposis after colectomy and ileorectal anastomosis. Ann Chir Gynaecol 1994;83:265-7.
18. Spagnesi MT, Tonelli F, Dolara P, Caderni G, Valanzano R, Anastasi A, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994;106:362-6.
19. Cerdan FJ, Torres-Melero J, Martinez S, Gutierrez del Olmo A, Balibrea JL. Treatment with sulindac of adenomatous polyps in familial polyposis. Rev Esp Enferm Dig 1995;87:574-6.
20. Kadmon M, Moslein G, Buhr HJ, Herfarth C. Desmoid tumors in patients with familial adenomatous polyposis (FAP). Clinical and therapeutic observations from the Heidelberg polyposis register. Chirurg 1995;66:997-1005.
21. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bunte H. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995;38:813-30.
22. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9.
23. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Randomised controlled trial of sulindac on intestinal polyposis in FAP. Gut 1992;33:S33.
24. Giardello FM, Hamilton SR, Krush AJ, Piantudosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
25. Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RK. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 1995;345:855-6.
26. Winde G, Schmid KW, Brandt B, Muller O, Osswald H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 1997;40:1156-68.
27. Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994;107:854-7.
28. Thorson AG, Lynch HT, Smyrk TC. Rectal cancer in FAP patient after sulindac. Lancet 1994;343:180.
29. Lynch HT, Thorson AG, Smyrk T. Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer 1995;75:936-8.
30. Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997;40:344-9.
31. Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-7.
32. Ishikawa H, Akedo I, Suzuki T, Narahara H, Otani T. Adverse effects of sulindac used for prevention of colorectal cancer. J Natl Cancer Inst 1997;89:1381.
33. Gridley G, McLaughlin JK, Ekborn A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-10.10.
34. Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996;14:551-3.
35. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691-6.
36. Laakso M, Mutru O, Isomaki H, Koota K. Cancer mortality in patients with rheumatoid arthritis. J Rheumatol 1986;13:522-6.
37. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illness, operations and medications: case-control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399-404.
38. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Schapiro S. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991;83:355-8.
39. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer and polyps of the large bowel. Cancer 1993;72:1171-7.
40. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 1994;74:1847-54.
41. Muller AD, Sonnenberg A, Wasseman IH. Diseases preceding colon cancer A case control study among veterans. Dig Dis Sci 1994;39:2480-4.
42. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9.
43. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 1996;5:955-60.
44. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996;91:44-8.
45. Evans JMM, McMahon AD, McGilchrist MM. Non-steroidal anti-inflammatory drugs, aspirin and colorectal cancer: a record linkage case control study in Tayside, Scotland (abstract). Gastroenterology 1995;114:A608.
46. La Vecchia C, Negri E, Franceschi S. Aspirin and colorectal cancer. Br J Cancer 1997;76:675-7.
47. Logan RFA, Little J, Hawtin PG, Harcastle JD. Effect of aspirin and non-steroidal drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult screening programme. Br Med J 1993;307:285-9.
48. Wishingrad M, Titzer D, Triadafopoulos G, Omary B. Chronic aspirin and NSAID use may protect against colorectal adenomas (abstract). Gastroenterology 1994;112:A452.
49. Johanson JF, Salisbury D. Effectiveness of aspirin in preventing colorectal adenomas: does dose matter ? (abstract). Gastroenterology 1995;114:A606.
50. Peleg, II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CM. Long-term use of nonsteroidal anti-inflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996;41:1319-26.
51. Macrae FA, Russell A, MacLennan R. Aspirin effects on large adenomas (abstract). Gastroenterology 1994;112:A413.
52. Martinez ME, McPherson RS, Levin B, Annegers JF. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 1995;4:703-7.
53. Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr A, Goebell H, et al. NSAIDs intake and the risk of colonic adenoma (abstract). Gastroenterology 1996;110:A1171.
54. Martinez ME, McPherson RS, Levin B, Glober GA. A case-control study of dietary intake and other lifestyle risk factors for hyperplastic polyps. Gastroenterology 1997;113:423-9.
55. Sandler R, Galanko J, Murray S, Helm J, Woosley J. Aspirin and non-steroidal anti-inflammatory agents prevent colorectal adenomas (abstract). Gastroenterology 1997;112:A789.
56. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study. Br Med J 1989;299:1247-50.
57. Paganini-Hill A, Hou G, Ross RK. Henderson BE. Aspirin use and incidence of large bowel cancer in a California retirement community. J Natl Cancer Inst 1991;83:1182-3.
58. Paganini-Hill A, Hsu G, Ross RK, Henderson BE. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1992;326:1290.
59. Schreinemachers DM, Everson RB. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
60. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
61. Slemmermann GN, Nomura AMY, Grove JS. Aspirin and colonic epithelium. Gastroenterology 1989;96:270-1.
62. Giovanucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
63. . Giovunucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
64. Greenberg ER, Baron JA, Freeman DJ, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users. J Natl Cancer Inst 1993;85:912-6.
65. Tosteson T, Greenberg E, Baron J. Aspirin use and reduced occurrence of large bowel adenomas (abstract). Gastroenterology 1995;108:A39.
66. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-27.
67. Gann PH Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin use and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1120-24.